Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain.
<h4>Background</h4>Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/07e2c17a9ecd490182090a7a1c6873aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:07e2c17a9ecd490182090a7a1c6873aa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:07e2c17a9ecd490182090a7a1c6873aa2021-11-18T07:18:25ZAdherence to interferon β-1b treatment in patients with multiple sclerosis in Spain.1932-620310.1371/journal.pone.0035600https://doaj.org/article/07e2c17a9ecd490182090a7a1c6873aa2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22615737/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice.<h4>Methodology/principal findings</h4>This was an observational, retrospective, cross-sectional study including 120 Spanish patients with MS under INFβ-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected medication, was 94.3%. The main reason for missing INFβ-1b injections was forgetting some of the administrations (64%). Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses injected per month, and should be considered in the management of adherence in MS patients.<h4>Conclusion/significance</h4>Among all the available methods for assessing adherence, the overall consumption of the intended dose has to be considered when addressing adherence.Oscar FernándezEduardo AgüeraGuillermo IzquierdoJorge Millán-PascualLluis Ramió I TorrentàPedro OlivaJoaquin ArgenteYasmina BerdeiJose Maria SolerOlga CarmonaJose Maria ErreaJordi FarrésGroup on Adherence to IFNb-1b in SpainPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 5, p e35600 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Oscar Fernández Eduardo Agüera Guillermo Izquierdo Jorge Millán-Pascual Lluis Ramió I Torrentà Pedro Oliva Joaquin Argente Yasmina Berdei Jose Maria Soler Olga Carmona Jose Maria Errea Jordi Farrés Group on Adherence to IFNb-1b in Spain Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| description |
<h4>Background</h4>Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice.<h4>Methodology/principal findings</h4>This was an observational, retrospective, cross-sectional study including 120 Spanish patients with MS under INFβ-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected medication, was 94.3%. The main reason for missing INFβ-1b injections was forgetting some of the administrations (64%). Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses injected per month, and should be considered in the management of adherence in MS patients.<h4>Conclusion/significance</h4>Among all the available methods for assessing adherence, the overall consumption of the intended dose has to be considered when addressing adherence. |
| format |
article |
| author |
Oscar Fernández Eduardo Agüera Guillermo Izquierdo Jorge Millán-Pascual Lluis Ramió I Torrentà Pedro Oliva Joaquin Argente Yasmina Berdei Jose Maria Soler Olga Carmona Jose Maria Errea Jordi Farrés Group on Adherence to IFNb-1b in Spain |
| author_facet |
Oscar Fernández Eduardo Agüera Guillermo Izquierdo Jorge Millán-Pascual Lluis Ramió I Torrentà Pedro Oliva Joaquin Argente Yasmina Berdei Jose Maria Soler Olga Carmona Jose Maria Errea Jordi Farrés Group on Adherence to IFNb-1b in Spain |
| author_sort |
Oscar Fernández |
| title |
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| title_short |
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| title_full |
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| title_fullStr |
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| title_full_unstemmed |
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. |
| title_sort |
adherence to interferon β-1b treatment in patients with multiple sclerosis in spain. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/07e2c17a9ecd490182090a7a1c6873aa |
| work_keys_str_mv |
AT oscarfernandez adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT eduardoaguera adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT guillermoizquierdo adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT jorgemillanpascual adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT lluisramioitorrenta adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT pedrooliva adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT joaquinargente adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT yasminaberdei adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT josemariasoler adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT olgacarmona adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT josemariaerrea adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT jordifarres adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain AT grouponadherencetoifnb1binspain adherencetointerferonb1btreatmentinpatientswithmultiplesclerosisinspain |
| _version_ |
1718423642519371776 |